Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088010 · ClinicalTrials.gov registry record · Phase 3
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,369
- Enrollment target
NCT00088010: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00088010 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 9,369 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088010, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,369 participants
- Enrollment target
Study Summary
The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. * Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health. * Effects of arzoxifene on the uterus. * The safety of arzoxifene and any side effects.
Interventions
- DRUG Placebo
- DRUG Arzoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,369 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00088010 record still lists
NCT00088010 is an interventional study that assigns participants to a tested intervention. Its 9,369 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1115% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00088010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088010 about?
NCT00088010 is a clinical study titled "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer". The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. * Effects of arzoxifene that changes the amount of ce...
What is the current status of trial NCT00088010?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,369 participants. The study started on 2004-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00088010?
The interventions under investigation include: Placebo (DRUG), Arzoxifene (DRUG).
Who is sponsoring clinical trial NCT00088010?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088010's enrollment target sits among peer trials
9,369 30th of 2000 higher than 1,971 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia